In conclusion, by demonstrating a wide spectrum of antiviral activity, a multi-genotypic anti-HCV activity, an additive to synergistic effect when combined with specific DAAs, and a high barrier to resistance—the new CypI STG-175 represents an attractive drug partner in IFN-free regimens for the treatment of HCV and co-infections. This evidence concerns the gene IFNA1 and coinfection.